The State and Growth of the UK Research-Peptide Market, 2019-2026

Edition 1, August 2026. Independent market research. Not medical advice.

Worldwide search interest in research peptides was flat for roughly four years, then broke out in a single compressed 14-month event starting mid-2025. This report tracks 211 UK-facing sellers, tests what UK retailers actually disclose about product testing, reviews the evidence base behind the most searched compounds, and live-tests how Google and AI platforms surface this market today. Every figure is graded A to E for reliability, and where no reliable public dataset exists, the report says so rather than filling the gap with an estimate.

Download the full report (PDF, 40 pages)

There is no reliable published figure for the size of the UK research-peptide retail market. This report says so plainly, and builds everything else from what can actually be verified.

Headline findings

Five things this report found

1. There is no reliable £ figure for the UK research-peptide retail market, and this report does not manufacture one. The market-research figures that circulate measure pharmaceutical peptide therapeutics or peptide manufacturing: different, licensed, B2B markets, not UK research-peptide retail.
2. Worldwide search interest broke out in a single compressed 14-month event, then pulled back sharply. Flat for roughly four years, a sharp break from June 2025, a peak in spring 2026, then a 50-65% pullback in the final weeks of data to mid-August 2026. Durability is unconfirmed.
3. Verifiable trust signals are the exception, not the norm, across the retailers this report tracked. Most show general reassurance language, but only around a third show a per-batch certificate of analysis, roughly a quarter name a specific lab partner, and only one in ten offer a QR-verifiable certificate.
4. AI platforms already name specific UK retailers today when asked trust and purchase questions, live now, not a future channel. Sourcing quality varies sharply by platform and query type, and no AI Overview appeared on any of the 12 live Google queries run for this report.
5. A combined "Market Growth Index" cannot be defensibly built from current data. Five of six proposed inputs fail on data-quality grounds. The one genuinely indexable input, a peptide-therapeutics publication index, measures the science base rather than the UK retail market.

### Trust-signal disclosure across the 211 UK-facing sellers this report tracked (August 2026)

| Signal | Count | Share |
| --- | --- | --- |
| Has a certificate of analysis (CoA) URL | 74 | 35.1% |
| CoA is per-batch (not one generic CoA for the catalogue) | 72 | 34.1% |
| CoA is QR-code verifiable to a third-party lab | 21 | 10.0% |
| Names a specific third-party lab partner | 55 | 26.1% |
| Companies House number recorded | 68 | 32.2% |
| Trustpilot URL recorded | 38 | 18.0% |
| Names any regulator or oversight body | 33 | 15.6% |

Source: PeptideClear, UK Research-Peptide Market Report (Edition 1, August 2026) (https://peptideclear.co.uk/research/uk-peptide-market-report/)

First-party assessment of 211 UK-facing sellers tracked by PeptideClear against a fixed certificate-of-analysis and company-verification rubric: 159 are classified research-peptide retailers assessed under this rubric, 36 await assessment, and 16 are GLP-1-adjacent or other. A separate, deeper per-retailer scoring of the assessed subset underpins the UK Peptide Transparency Index and PeptideClear Trust Index. This table measures transparency and company verification only; it makes no health, safety or product claim.

The evidence gap behind the two most searched compounds

The clearest search-versus-evidence gap sits in the two most commercially central UK compounds. BPC-157 has 226 PubMed papers in total, roughly 2.7 to 3 times the publication count of 2010-14, but around 65% of that literature is explicitly animal-tagged and there are essentially no published human randomised controlled trials. TB-500 (Thymosin Beta-4) shows a declining publication rate on the broad parent-molecule search term over the same window. Both compounds show search interest running well ahead of a thin, mostly preclinical evidence base. The full report reviews the evidence base for ten individual compounds against their search-growth rank.

How this market shows up in Google and AI search

This report live-tested 12 Google searches, 8 Perplexity prompts, 3 ChatGPT prompts and 1 Gemini prompt against real UK peptide-market queries in August 2026. No AI Overview appeared on any of the 12 Google queries tested: this category currently sits outside Google's own AI-generated results, even though AI Overviews cover 80-90% of healthcare and informational queries industry-wide. On generic trust and legitimacy questions, sourcing on AI chat platforms is often weak: Perplexity's citations were 100% retailer-authored content in every query checked, and Gemini named retailers and specific technical claims with zero citations at all. For specific "is [named UK retailer] legitimate" queries, results draw more heavily on organic search visibility, and PeptideClear's own page-one ranking for named-retailer trust queries is reported separately in the full report because PeptideClear is this report's publisher, not as independent validation of PeptideClear.

What's in the full report

The 40-page PDF covers 24 sections and a data appendix: how much the market has grown and when, search demand and the fastest-growing individual compounds, what has driven the growth (including the GLP-1 mainstreaming question), the UK retailer landscape and pricing, trust and verification across tracked sellers, scientific publication trends by compound, the Google and AI search landscape, regulation and market risk, UK-versus-international development, why a combined "Market Growth Index" could not be defensibly built, and what to track going forward.

Download the full report (PDF, 40 pages)

Methodology

Every claim in this report is graded A to E for reliability: A for primary, regulator or first-party data directly verified (including PeptideClear's own directly-observed dataset, labelled as such at the point of use); B for a live database or survey query, reproducible and low-ambiguity; C for a reasonable proxy, a worldwide-not-UK figure, a small sample, or a single-pull dataset; D for weak, self-reported or thin-sample data; and E for a vendor marketing claim or an unverifiable figure, excluded from headline claims. Wherever no reliable public dataset exists, the report states that plainly rather than estimating a number to fill the gap. See our general methodology for how PeptideClear sources and verifies claims across the site.

Download the data

The full report is free to download as a PDF. The trust-signal indicator table above is also available as a CSV under a Creative Commons Attribution 4.0 licence:

UK Research-Peptide Market Report, August 2026 (PDF)

Trust-signal indicator table, August 2026 (CSV)

Compiled by Oliver Mackman. Published by PeptideClear. See also the UK Peptide Transparency Index, the PeptideClear Trust Index and our UK peptide statistics.